Cell Signaling & Oncology
The signaling pathways controlling cell growth and differentiation are almost invariably altered in cancer. During the course of tumor progression, cancer cells acquire a number of characteristic alterations. These include the capacities to proliferate independently of exogenous growth-promoting or growth-inhibitory signals, to invade surrounding tissues and metastasize to distant sites, to elicit an angiogenic response, and to evade mechanisms that limit cell proliferation, such as apoptosis and replicative senescence. These properties reflect alterations in the cellular signaling pathways that in normal cells control cell proliferation, motility, and survival. These interconnected pathways are being deciphered, but understanding the alterations that lead to cancer and correcting them is a substantial challenge. Among the key pathways are those controlling cell proliferation, which coordinate a response to the cellular environment, with the mTOR kinase as a critical node. Tumour development is influenced by infections and inflammation, and the complex role of the nuclear factor-B transcription factors is being unravelled. Expansion of tumour cells depends on nutrient supply and vascularization, which is orchestrated by the transcription factor known as HIF. And the metastatic spread of primary tumours to other organs is facilitated by many signaling pathways[1],[2].
Cell Signaling and Oncology products Library
For your convenience, you can order a library of all of our Cell Signaling and Oncology research related products. Make your personal library by cherry picking products of your interest from our comprehensive list (>800 products), or order all together not to miss any. The libraries will be shipped as 10 mM solutions (in DMSO, 250 µL of each selected Axon Ligand™) on a 96-well microtiter plate with a clear map of its contents.
Simply download our comprehensive list of epigenetics products below (Microsoft Excel (.xls)), check the products to be included, and return your list to order the library of your preference.
 Axon 5051 - Cell signaling and Oncology Library.xls |
|
[1] A. Eccleston, R. Dhand. Signalling in cancer. Nature 441, 423, editorial note
[2] G.S. Martin. Cell signaling and cancer. Cancer Cell. 2003 Sep;4(3):167-74.
| Axon ID | Name | Description | From price | |
|---|---|---|---|---|
| 1526 | Neratinib | EGFR and ErbB-2/HER2 tyrosine kinase inhibitor | €80.00 | |
| 1396 | Nilotinib | BCR-ABL inhibitor | €50.00 | |
| 3168 | Nilotinib hydrochloride | BCR-ABL inhibitor | €70.00 | |
| 1137 | PD180970 | Bcr-Abl tyrosine kinase inhibitor (p210 specific) | €120.00 | |
| 2546 | PF 06447475 | Potent, selective, brain penetrant, and in vivo active LRRK2 kinase inhibitor | €85.00 | |
| 1792 | PF 4800567 | Inhibitor of Casein kinase 1 (CK1-ε) | €95.00 | |
| 1623 | PF 573228 | FAK inhibitor | €95.00 | |
| 2459 | PND 1186 | Orally active dual FAK/PYK2 inhibitor triggering cell apoptosis in tumor cells | €90.00 | |
| 2920 | Poziotinib | Irreversible pan-HER inhibitor | €95.00 | |
| 3154 | rac-BRD0705 | GSK3α inhibitor | €120.00 | |
| 2677 | RIPA-56 | RIP1 inhibitor for the treatment of systemic inflammatory response syndrome | €60.00 | |
| 2229 | RKI 1447 | Potent inhibitor of the Rho-associated ROCK kinases | €105.00 | |
| 1303 | SB 216763 | GSK-3 inhibitor | €85.00 | |
| 1633 | SGI 1776 free base | Pim kinase inhibitor | €95.00 | |
| 1407 | SKI 606 | Bcr-Abl and Src tyrosine kinase inhibitor | €75.00 | |
| 1923 | SMI 4a | ATP-competitive and selective inhibitor of Pim kinases | €75.00 | |
| 1635 | Sotrastaurin | PKC inhibitor | €50.00 | |
| 2547 | SR 3029 | A potent, highly specific CK1δ/CK1ε inhibitor | €135.00 | |
| 5009 | Stem Cell 4i inhibitor Set | Set of Thiazovivin, SB 431542, PD0325901, and CHIR99021 (inhibitors of ROCK, TGF-β, MEK, and GSK-3 resp.) | €170.00 | |
| 5007 | Stem Cell 5i inhibitor Set | Set of five inhibitors for neural differentiation of human pluripotent stem cells. | €200.00 | |
| 2130 | Stem Cell Alternative 2i inhibitor Set | Set of SRC inhibitor CGP77675 (Axon 2097) and GSK-3 inhibitor CHIR99021 (Axon 1386) | €110.00 | |
| 5006 | Stem Cell CSD inhibitor Set | Set of CHIR99021, SU5402, and DAPT, inhibitors of GSK-3, FGFR, and γ-secretase, resp. | €140.00 | |
| 3232 | TAK-788 | Potent and selective EGFR and ErbB-2/HER2 tyrosine kinase inhibitor | €70.00 | |
| 1535 | Thiazovivin | ROCK inhibitor and iPSC stimulator; Stem cell related | €90.00 | |
| 3579 | Tideglusib | GSK-3 inhibitor | €60.00 | |
| 2560 | Tilfrinib | Brk inhibitor with antiproliferative activity in breast tumor cells | €95.00 | |
| 3099 | TL02-59 | Potent, selective and orally active Fgr and Lyn inhibitor | €120.00 | |
| 1854 | TTP 22 | Inhibitor of Casein kinase 2 (CK2) | €105.00 | |
| 1562 | TWS 119 | GSK-3β inhibitor | €70.00 | |
| 2381 | WH-4-023 | Orally active src-family selective lck inhibitor | €90.00 | |